FA
IBB icon

Financial Advantage’s iShares Biotechnology ETF IBB Stock Holding History

Financial Advantage’s Portfolio IBB Stock Details IBB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-570
Closed -$56K – 114
2019
Q3 		$56K Buy
+570
New +$59.7K 0.04% 68

Other funds holding IBB

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Financial Advantage's IBB Position: Q4 2019 in Review

Financial Advantage sold out of iShares Biotechnology ETF (IBB) in Q4 2019, closing a stake of 570 shares — an estimated $56K sold.

Financial Advantage first reported a position in IBB in Q3 2019 and held it in 1 quarter. The position peaked at $56K in Q3 2019. 710 funds tracked by Wall St. Rank hold IBB as of Q4 2019.

  • Financial Advantage reported no remaining iShares Biotechnology ETF position as of Q4 2019 after selling out during the quarter.
  • Financial Advantage sold 570 iShares Biotechnology ETF shares in Q4 2019, an estimated $56K.
  • Financial Advantage first reported a position in iShares Biotechnology ETF in Q3 2019 and held it in 1 quarter.
  • Financial Advantage's iShares Biotechnology ETF position peaked at $56K in Q3 2019.
  • 710 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2019.

Based on Financial Advantage's 13F filing for Q4 2019, filed 31 Jan 2020.